Legend Biotech
Update in progressLEGN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Legend Biotech is a biopharmaceutical company that discovers, develops, manufactures, and markets novel cell therapies for oncology in the United States, China, and Europe. Its lead product, cilta-cel (CAR-T) for multiple myeloma, is partnered with Janssen. The pipeline includes autologous CAR-T candidates for various cancers and allogeneic gamma delta CAR-T and CAR-NK therapies targeting BCMA in China. It also licenses delta-like ligand 3 therapies from Novartis. Founded 2014; based in Somerset, NJ.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Ying Huang Ph.D.
- Founded2014
- Employees3,200
- Websitelegendbiotech.com
Identifiers
- ISINUS52490G1022
- FIGIBBG00TTGH5W4
- LEI254900EIUFZTW136H859
- CUSIP52490G102
- CIK0001801198